Scholar Rock Q3 2021 Earnings Report
Key Takeaways
Scholar Rock reported third quarter 2021 financial results, with a net loss of $37.5 million, or $1.02 per share, compared to a net loss of $23.6 million, or $0.79 per share for the quarter ended September 30, 2020. Revenue was $5.5 million, compared to $3.0 million for the quarter ended September 30, 2020. The company is on track to initiate the Phase 3 pivotal trial evaluating apitegromab in patients with non-ambulatory Type 2 and Type 3 SMA by year-end 2021.
Phase 3 pivotal trial evaluating apitegromab in patients with non-ambulatory Type 2 and Type 3 SMA on track to initiate by year-end 2021.
Update from Part A of the DRAGON Phase 1 trial evaluating SRK-181’s ability to overcome primary resistance to checkpoint inhibitors being presented at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting.
Initiated Part B dose expansion portion of the DRAGON trial.
U.S. patent issued providing additional product protection for SRK-181 to May 2040.
Scholar Rock
Scholar Rock
Forward Guidance
Scholar Rock is well-funded to continue executing on its development programs while continuing to invest in its robust discovery platform.